SOPHiA GENETICS SA (NASDAQ:SOPH) Stock Has Consensus Target Price of $10.00 According to Brokerages

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) have received a consensus recommendation of “Hold” from the five ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $10.00.

Several analysts have recently commented on SOPH shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, October 15th. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. BTIG Research upped their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, HC Wainwright reissued a “buy” rating and set a $14.00 price objective on shares of SOPHiA GENETICS in a report on Monday, October 12th.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $14 price target, signaling continued analyst confidence despite lowering its forecasts. SOPHiA GENETICS brokerage coverage
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across the second half of 2026 and all four quarters of 2027. Its FY2026 estimate moved to a loss of $0.94 per share from $0.77, while its FY2027 estimate shifted to a loss of $0.49 from $0.31. The deeper projected losses are a negative signal for profitability expectations.

SOPHiA GENETICS Stock Performance

SOPH opened at $7.14 on Friday. SOPHiA GENETICS has a 1-year low of $3.83 and a 1-year high of $8.98. The stock’s 50 day simple moving average is $7.70 and its 200 day simple moving average is $5.99. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The stock has a market cap of $598.97 million, a P/E ratio of -6.55 and a beta of 1.09.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The company had revenue of $24.27 million for the quarter, compared to analyst estimates of $24.03 million. As a group, equities analysts anticipate that SOPHiA GENETICS will post -0.94 EPS for the current fiscal year.

Insider Buying and Selling at SOPHiA GENETICS

In other news, insider Well Van sold 6,168 shares of the stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $8.12, for a total value of $50,084.16. Following the sale, the insider directly owned 332,716 shares of the company’s stock, valued at approximately $2,701,653.92. This represents a 1.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Zhenyu Xu sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 13th. The stock was sold at an average price of $7.18, for a total transaction of $28,720.00. Following the completion of the sale, the insider owned 541,493 shares in the company, valued at $3,887,919.74. This represents a 0.73% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 170,662 shares of company stock valued at $1,372,619 over the last quarter. Company insiders own 4.88% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Sowell Financial Services LLC acquired a new stake in shares of SOPHiA GENETICS in the third quarter valued at approximately $2,865,000. Maven Securities LTD acquired a new stake in SOPHiA GENETICS during the second quarter worth about $866,000. AXQ Capital LP bought a new position in shares of SOPHiA GENETICS during the second quarter worth about $119,000. AWM Investment Company Inc. bought a new position in shares of SOPHiA GENETICS in the second quarter valued at $9,809,000. Finally, Hennion & Walsh Asset Management Inc. bought a new stake in shares of SOPHiA GENETICS in the second quarter valued at $567,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a healthcare technology company that develops data-driven solutions for genomic medicine. Its cloud-based platform uses artificial intelligence, machine learning and advanced analytics to help healthcare organizations analyze and interpret complex biological and clinical data.

The company’s primary offering, the SOPHiA DDM platform, supports next-generation sequencing workflows, including data management, quality control, genomic analysis, variant interpretation and reporting.